Literature DB >> 34964502

Mutational and phylogenetic analyses of the two lineages of the Omicron variant.

Swagata Majumdar1, Rakesh Sarkar2.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 34964502      PMCID: PMC9015627          DOI: 10.1002/jmv.27558

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


× No keyword cloud information.
Dear Editor, Based on the recommendation of the WHO's Technical Advisory Group on Virus Evolution, WHO designated the variant B.1.1.529 as a variant of concern (VOC) and named Omicron on 26 November, 2021. Omicron was first observed in Africa in mid‐November 2021. The infection by this variant has been rapidly spreading and 85 countries have already reported the cases of human infection with this variant as of 15 December 2021. The rapid spread of Omicron has again fueled the fears of COVID‐19 all around the world like other four VOCs (Alpha, Beta, Gamma, and Delta). Recently, the Omicron variant has classified into two different lineages BA.1 and BA.2 based on the mutations, some of which are common and some are unique to both lineages. , Still, there is no clear evidence or published article on the mutational diversity and phylogenetic analysis of these two lineages. Therefore, in the present study, we have performed the whole‐genome mutational mapping and phylogenetic analysis of BA.1 and BA.2 lineages. We have downloaded 6 genome sequences each of BA.1 and BA.2, and also the genome sequence of the prototype strain (hCoV‐19/Wuhan/WIV04/2019) from the Global Initiative on Sharing All Influenza Data (GISAID) and performed whole‐genome mutational analysis according to the protocol described in Sarkar et al. , Each of the six genomes of both BA.1 and BA.2 lineages was found to have 51 mutations dispersed throughout the genome, 32 of which are common to both lineages, whereas each lineage has 19 signature mutations. Among 32 common mutations, 21 are present in the S glycoprotein and the rest 11 are present in the other four coding regions (ORF1ab, E, M, and N). Nineteen unique mutations of BA.1 include 13 in the S glycoprotein and that of BA.2 includes 7 in the S glycoprotein (Table 1). Phylogenetic analysis of 12 genome sequences of Omicron variant, encompassing 6 genomes each of BA.1 and BA.2, along with the 2000 genomes of 25 different clades by Ultrafast Sample placement of Existing tRees, , revealed that genomes of Omicron variant formed a new cluster that emerged from the 20B clade (also known as GR) and also subdivided into two different subclusters (BA.1 and BA.2) based on the unique mutations (Figure 1).
Table 1

List of common and unique mutations present within the genome of BA.1 and BA.2 lineages

Note: Red color indicates the mutations of the receptor‐binding domain (RBD) of S glycoprotein. Violet color indicates the mutation of the N‐terminal domain (NTD) of S glycoprotein.

Figure 1

Phylogenetic analysis of the Omicron variant by Ultrafast Sample placement of Existing tRee (UShER). The phylogenetic tree (unrooted tree) was constructed with a total of 2012 SARS‐CoV‐2 strains involving 12 strains of the Omicron variant (red color) and 2000 strains from 25 different clades. Each color in the tree is representing a different clade/lineage

List of common and unique mutations present within the genome of BA.1 and BA.2 lineages Note: Red color indicates the mutations of the receptor‐binding domain (RBD) of S glycoprotein. Violet color indicates the mutation of the N‐terminal domain (NTD) of S glycoprotein. Phylogenetic analysis of the Omicron variant by Ultrafast Sample placement of Existing tRee (UShER). The phylogenetic tree (unrooted tree) was constructed with a total of 2012 SARS‐CoV‐2 strains involving 12 strains of the Omicron variant (red color) and 2000 strains from 25 different clades. Each color in the tree is representing a different clade/lineage The S glycoprotein mediates virus attachment to ACE2 receptor, membrane fusion, and entry into the host cell, and also acts as a primary target for neutralizing antibodies elicited by the host immune response. Presence of 34 and 28 mutations in the S glycoprotein of BA.1 and BA.2, respectively, raising concern whether these lineages have increased transmissibility, immune escape potential, and virulence compared to other circulating SARS‐CoV‐2 strains especially Delta which is currently dominating worldwide. Seven mutations of both BA.1 and BA.2 (G142D, K417N, T478K, N501Y, D614G, H655Y, and P681H) and three mutations of BA.1 (∆HV69del, T95I, and ∆YY144del) overlap four other VOCs (Alpha, Beta, Gamma, and Delta) and have previously been linked with high transmissibility, increased viral binding affinity, and immune evasion. , , , Functional implication of the remaining mutations of the S glycoprotein and other coding regions of BA.1 and BA.2 still unknown, leaving a question of how the whole set of mutations of the two lineages will affect viral fitness. Preliminary evidence indicated that Omicron has increased infectivity and a high transmission rate compared to Delta. , , However, whether the rapid spread of Omicron in countries with increased population immunity is due to increased transmissibility and/or immune evasion remains unclear. Though, some recent studies have claimed the immune evasion properties of the Omicron. , , , Based on this existing evidence, Omicron is anticipated to overtake Delta in areas where community transmission occurs. The severity of Omicron infection still remains elusive. Preliminary studies from South Africa suggested that Omicron may be less severe than Delta, and all COVID‐19 patients, infected with Omicron, from countries of EU and EEA either showed mild symptoms or were asymptomatic. Detection accuracy of routinely used PCR and antigen‐based rapid diagnostic test (Ag‐RDT) assays was not found to be influenced by most of the Omicron strains. However, the BA.1 lineage showed S gene target failure (SGTF) in RT‐PCR assay due to multiple deletions in the NTD of S glycoprotein, whereas BA.2 lineage may skip SGTF due to lack of deletions in the NTD. Overall, the global threat related to Omicron remains very high for its potential to escape humoral immune response and high transmissibility, which may lead to another wave of COVID‐19 with severe consequences.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

Swagata Majumdar and Rakesh Sarkar conceived the study. Swagata Majumdar performed sequence retrieval of SARS‐CoV‐2 and whole‐genome mutational analysis. Rakesh Sarkar performed the phylogenetic analysis and drafted the manuscript. All authors revised the manuscript and approved the final manuscript for submission.
  13 in total

1.  Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa.

Authors:  Lulan Wang; Genhong Cheng
Journal:  J Med Virol       Date:  2021-12-27       Impact factor: 2.327

2.  Spike mutation D614G alters SARS-CoV-2 fitness.

Authors:  Jessica A Plante; Yang Liu; Jianying Liu; Hongjie Xia; Bryan A Johnson; Kumari G Lokugamage; Xianwen Zhang; Antonio E Muruato; Jing Zou; Camila R Fontes-Garfias; Divya Mirchandani; Dionna Scharton; John P Bilello; Zhiqiang Ku; Zhiqiang An; Birte Kalveram; Alexander N Freiberg; Vineet D Menachery; Xuping Xie; Kenneth S Plante; Scott C Weaver; Pei-Yong Shi
Journal:  Nature       Date:  2020-10-26       Impact factor: 49.962

3.  Ultrafast Sample placement on Existing tRees (UShER) enables real-time phylogenetics for the SARS-CoV-2 pandemic.

Authors:  Yatish Turakhia; Bryan Thornlow; Angie S Hinrichs; Nicola De Maio; Landen Gozashti; Robert Lanfear; David Haussler; Russell Corbett-Detig
Journal:  Nat Genet       Date:  2021-05-10       Impact factor: 41.307

4.  Mutation D614G increases SARS-CoV-2 transmission.

Authors:  Prerna Arora; Stefan Pöhlmann; Markus Hoffmann
Journal:  Signal Transduct Target Ther       Date:  2021-03-01

5.  Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations.

Authors:  Rakesh Sarkar; Suvrotoa Mitra; Pritam Chandra; Priyanka Saha; Anindita Banerjee; Shanta Dutta; Mamta Chawla-Sarkar
Journal:  Arch Virol       Date:  2021-01-19       Impact factor: 2.574

6.  Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India.

Authors:  Rakesh Sarkar; Ritubrita Saha; Pratik Mallick; Ranjana Sharma; Amandeep Kaur; Shanta Dutta; Mamta Chawla-Sarkar
Journal:  J Infect Public Health       Date:  2021-12-04       Impact factor: 3.718

7.  SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance.

Authors:  Xiantao Zhang; Shijian Wu; Bolin Wu; Qirui Yang; Achun Chen; Yuzhuang Li; Yiwen Zhang; Ting Pan; Hui Zhang; Xin He
Journal:  Signal Transduct Target Ther       Date:  2021-12-17

8.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.

Authors:  Alexandra C Walls; Young-Jun Park; M Alejandra Tortorici; Abigail Wall; Andrew T McGuire; David Veesler
Journal:  Cell       Date:  2020-03-09       Impact factor: 41.582

9.  Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.

Authors:  Allison J Greaney; Tyler N Starr; Pavlo Gilchuk; Seth J Zost; Elad Binshtein; Andrea N Loes; Sarah K Hilton; John Huddleston; Rachel Eguia; Katharine H D Crawford; Adam S Dingens; Rachel S Nargi; Rachel E Sutton; Naveenchandra Suryadevara; Paul W Rothlauf; Zhuoming Liu; Sean P J Whelan; Robert H Carnahan; James E Crowe; Jesse D Bloom
Journal:  Cell Host Microbe       Date:  2020-11-19       Impact factor: 31.316

10.  Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.

Authors:  Nicole Wolter; Waasila Jassat; Sibongile Walaza; Richard Welch; Harry Moultrie; Michelle Groome; Daniel Gyamfi Amoako; Josie Everatt; Jinal N Bhiman; Cathrine Scheepers; Naume Tebeila; Nicola Chiwandire; Mignon du Plessis; Nevashan Govender; Arshad Ismail; Allison Glass; Koleka Mlisana; Wendy Stevens; Florette K Treurnicht; Zinhle Makatini; Nei-Yuan Hsiao; Raveen Parboosing; Jeannette Wadula; Hannah Hussey; Mary-Ann Davies; Andrew Boulle; Anne von Gottberg; Cheryl Cohen
Journal:  Lancet       Date:  2022-01-19       Impact factor: 202.731

View more
  29 in total

1.  Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1-BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa.

Authors:  Rabia Johnson; Noluxabiso Mangwana; Jyoti R Sharma; Christo J F Muller; Kholofelo Malemela; Funanani Mashau; Stephanie Dias; Pritika Ramharack; Craig Kinnear; Brigitte Glanzmann; Amsha Viraragavan; Johan Louw; Swastika Surujlal-Naicker; Sizwe Nkambule; Candice Webster; Mongezi Mdhluli; Glenda Gray; Angela Mathee; Wolfgang Preiser; Alvera Vorster; Shareefa Dalvie; Renee Street
Journal:  J Infect Dis       Date:  2022-10-17       Impact factor: 7.759

2.  Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.

Authors:  Hirofumi Ohashi; Takayuki Hishiki; Daisuke Akazawa; Kwang Su Kim; Joohyeon Woo; Kaho Shionoya; Kana Tsuchimoto; Shoya Iwanami; Saya Moriyama; Hitomi Kinoshita; Souichi Yamada; Yudai Kuroda; Tsukasa Yamamoto; Noriko Kishida; Shinji Watanabe; Hideki Hasegawa; Hideki Ebihara; Tadaki Suzuki; Ken Maeda; Shuetsu Fukushi; Yoshimasa Takahashi; Shingo Iwami; Koichi Watashi
Journal:  Antiviral Res       Date:  2022-07-04       Impact factor: 10.103

3.  COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme.

Authors:  Clare L Fasching; Venice Servellita; Bridget McKay; Vaishnavi Nagesh; James P Broughton; Alicia Sotomayor-Gonzalez; Baolin Wang; Noah Brazer; Kevin Reyes; Jessica Streithorst; Rachel N Deraney; Emma Stanfield; Carley G Hendriks; Becky Fung; Steve Miller; Jesus Ching; Janice S Chen; Charles Y Chiu
Journal:  J Clin Microbiol       Date:  2022-06-29       Impact factor: 11.677

4.  Development of a simple genotyping method based on indel mutations to rapidly screen SARS-CoV-2 circulating variants: Delta, Omicron BA.1 and BA.2.

Authors:  Wajdi Ayadi; Awatef Taktak; Saba Gargouri; Fahmi Smaoui; Amel Chtourou; Houda Skouri-Gargouri; Rihab Derbel; Azza Hadj Sassi; Ali Gargouri; Adnene Hammami; Héla Karray-Hakim; Raja Mokdad-Gargouri; Lamia Fki-Berrajah
Journal:  J Virol Methods       Date:  2022-06-18       Impact factor: 2.623

5.  An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.

Authors:  Lianghui Zhang; Krishna K Narayanan; Laura Cooper; Kui K Chan; Christine A Devlin; Aaron Aguhob; Kristie Shirley; Lijun Rong; Jalees Rehman; Asrar B Malik; Erik Procko
Journal:  bioRxiv       Date:  2022-03-28

Review 6.  The Emergence of Omicron: Challenging Times Are Here Again!

Authors:  Tanu Singhal
Journal:  Indian J Pediatr       Date:  2022-01-13       Impact factor: 5.319

Review 7.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Authors:  Rekha Khandia; Shailja Singhal; Taha Alqahtani; Mohammad Amjad Kamal; Nahed A El-Shall; Firzan Nainu; Perumal Arumugam Desingu; Kuldeep Dhama
Journal:  Environ Res       Date:  2022-01-29       Impact factor: 8.431

Review 8.  Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review.

Authors:  Giorgio Tiecco; Samuele Storti; Melania Degli Antoni; Emanuele Focà; Francesco Castelli; Eugenia Quiros-Roldan
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

9.  Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.

Authors:  Yoshihiro Kawaoka; Ryuta Uraki; Maki Kiso; Shun Iida; Masaki Imai; Emi Takashita; Makoto Kuroda; Peter Halfmann; Samantha Loeber; Tadashi Maemura; Seiya Yamayoshi; Seiichiro Fujisaki; Zhongde Wang; Mutsumi Ito; Michiko Ujie; Kiyoko Iwatsuki-Horimoto; Yuri Furusawa; Ryan Wright; Zhenlu Chong; Seiya Ozono; Atsuhiro Yasuhara; Hiroshi Ueki; Yuko Sakai; Rong Li; Yanan Liu; Deanna Larson; Michiko Koga; Takeya Tsutsumi; Eisuke Adachi; Makoto Saito; Shinya Yamamoto; Shohei Matsubara; Masao Hagihara; Keiko Mitamura; Tetsuro Sato; Masayuki Hojo; Shin-Ichiro Hattori; Kenji Maeda; Moe Okuda; Jurika Murakami; Calvin Duong; Sucheta Godbole; Daniel Douek; Shinji Watanabe; Norio Ohmagari; Hiroshi Yotsuyanagi; Michael Diamond; Hideki Hasegawa; Hiroaki Mitsuya; Tadaki Suzuki
Journal:  Res Sq       Date:  2022-02-24

Review 10.  SARS-CoV-2 Omicron variant: Immune escape and vaccine development.

Authors:  Danyi Ao; Tianxia Lan; Xuemei He; Jian Liu; Li Chen; Daniel T Baptista-Hon; Kang Zhang; Xiawei Wei
Journal:  MedComm (2020)       Date:  2022-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.